Vis enkel innførsel

dc.contributor.authorRodriguez-Porcel, Federico
dc.contributor.authorWyman-Chick, Kathryn A.
dc.contributor.authorAbdelnour Ruiz, Carla
dc.contributor.authorToledo, Jon B.
dc.contributor.authorFerreira, Daniel
dc.contributor.authorUrwyler, Prabitha
dc.contributor.authorWeil, Rimona S.
dc.contributor.authorKane, Joseph
dc.contributor.authorPilotto, Andrea
dc.contributor.authorRongve, Arvid
dc.contributor.authorBoeve, Bradley
dc.contributor.authorTaylor, John-Paul
dc.contributor.authorMcKeith, Ian
dc.contributor.authorAarsland, Dag
dc.contributor.authorLewis, Simon J. G.
dc.date.accessioned2022-09-30T12:48:38Z
dc.date.available2022-09-30T12:48:38Z
dc.date.created2022-09-13T10:43:07Z
dc.date.issued2022
dc.identifier.issn2096-6466
dc.identifier.urihttps://hdl.handle.net/11250/3022947
dc.description.abstractThe selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer’s or Parkinson’s disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleClinical outcome measures in dementia with Lewy bodies trials: critique and recommendationsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.articlenumber24en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1186/s40035-022-00299-w
dc.identifier.cristin2051108
dc.source.journalTranslational Neurodegenerationen_US
dc.identifier.citationTranslational Neurodegeneration. 2022, 11, 24.en_US
dc.source.volume11en_US
dc.source.issue1en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal